New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
08:12 EDTESPREsperion Therapeutics initiates Phase 2 study of ETC-1002
Esperion Therapeutics announced dosing of the first patient in its Phase 2 clinical study of ETC-1002 in patients with hypercholesterolemia and hypertension, ETC-1002-014. The company expects to announce top-line results from the study in the second quarter of 2015. The randomized, double-blind, parallel group, multicenter ETC-1002-014 study is evaluating parallel doses of ETC-1002 in approximately 144 patients. The primary objective of the study is to assess the LDL-cholesterol lowering efficacy of ETC-1002 monotherapy versus placebo in patients with both hypercholesterolemia and hypertension who are treated for six weeks. Secondary objectives include assessing the effect of ETC-1002 on blood pressure, other lipid and cardiometabolic biomarkers and characterizing the tolerability and safety of ETC-1002.
News For ESPR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:07 EDTESPREsperion cholesterol drug a blockbuster if approved, says Citigroup
Citigroup believes Esperion's cholesterol lowering drug ETC-1002 is an inevitable blockbuster if approved. Citi views the company's market cap as disproportionate to the remaining risks around the drug. It says it continues to be a buyer of the stock and raised its price target for Esperion shares to $35 from $30.
September 26, 2014
08:49 EDTESPREsperion phase II trial likely to be successful, says Summer Street
Subscribe for More Information
07:32 EDTESPRBioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
September 25, 2014
08:59 EDTESPRSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use